Successful Trial to Cure Hemophilia Conducted with Participation of Israelis

Hemophilia, which is a rare bleeding disorder, may have met its match thanks to an innovative new treatment that has been trialed with success by Israeli researchers. Hemophilia patients are unable to clot their blood, which can result in severe injuries or even death. For years, hemophilia has been treated with regular infusions of clotting factor, which can be potentially dangerous, time-consuming, and expensive. However, a new gene therapy has been developed that enables the body to produce its own clotting factor, potentially freeing hemophilia sufferers from the life-long burden of regular treatments. In this article, we’ll take a closer look at this revolutionary new treatment and the Israeli researchers who were instrumental in developing it.


A recent international study on hemophilia, which included the Sheba Medical Center in Israel, accomplished an extraordinary feat by curing participants with the genetic disease. The findings, published in The New England Journal of Medicine, revealed that the researchers successfully replaced the defective gene responsible for causing hemophilia with a healthy gene delivered via a virus. By replicating this gene, the participants’ condition was cured.

Hemophilia is a congenital illness that hinders the production of clotting protein 8 (Factor 8) due to genetic mutation. All patients with this illness, who are males, are born with this disorder. Patients with severe hemophilia experience spontaneous bleeding in the muscles and joints, which can lead to orthopedic disabilities starting at an early age.

The study included 134 elderly patients with hemophilia, five of whom were from Israel. According to Prof. Gili Kenet, the Director of the Israel National Hemophilia Center and Thrombosis Institute in Sheba Medical, “We were able to cure a person suffering from a serious genetic disease within just a few months.” She further stated that all the Israeli participants in the experiment were cured of the disease, had no bleeding issues, and showed normal levels of the Factor 8 protein.

However, six of the participants who were part of the trial still had moderate hemophilia, although their bleeding had decreased significantly. It was once considered science fiction but is now reality, said Prof. Kenet.

Approximately 700 individuals in Israel have hemophilia, and early detection is standard practice in the country, as it is often detected during circumcision due to the possibility of excessive bleeding. Patients with hemophilia, at the time of testing, had to undergo repeated transfusions to replace the missing factor in their blood. They received these transfusions frequently to prevent severe bleeding and possible disability.

The trial, which was conducted by BioMarin and included 50 medical centers in 30 countries, has already submitted its treatment for FDA approval, which will have significant implications for the condition worldwide.


In conclusion, the successful clinical trial in Israel to cure hemophilia is a groundbreaking achievement that brings hope to people living with this challenging condition. The Israeli scientific community has once again demonstrated its ingenuity and dedication to finding innovative solutions to medical problems. This breakthrough could have a significant impact on the lives of those living with the condition, along with their loved ones. The results of the trial reinforce the importance of continued investment in research, and it’s a reminder of the power of science to improve the quality of life for people across the globe. It’s truly inspiring to see amazing advancements in medical science, and we can only hope that this innovation will continue to push the boundaries of what is possible.